Oncolys BioPharma is a public clinical-stage company developing oncolytic viruses . OBP-301 is the first-in-class oncolytic adenovirus for Esophageal Cancer. In a pivotal Phase II study conducted in Japan, OBP-301 has shown promising efficacy in combination with radiation therapy. NDA submitted to PMDA, December 15, 2025. If all goes well, OBP-301 will be the first world's approval for an oncolytic virus for Esophageal Cancer.

We are also developing HDAC inhibitor and small molecule

anti-SARS-Cov-2, and cancer diagnostic

In the US, OBP-301 has demonstrated safety and efficacy as monotherapy and in combination with Chemoradiotherapy. In phase 1 study (NRG-GI007) of OBP-301 and definitive chemoradiation in locally advanced esophageal cancer OBP-301 demonstrated very promising cCR rate. Among 13 patients

who were evaluable,100 % cCR rate was observed.

We are seeking strategic partnerships and investment opportunities to advance the development of OBP-301 in the US. Contact; +1-551-444-2666